Treatment of Lymph Node-Negative, Early-Stage HER2-Positive Breast Cancer

被引：1
|
作者：
Oguz, Arzu [1 ]
Keskin, Gul Sema [1 ]
Colak, Dilsen [1 ]
Altundag, Ozden [1 ]
Akcali, Zafer [1 ]
机构：
[1] Baskent Univ, Bahcelievler Ankara, Turkey
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 06期
关键词：
ADJUVANT TRASTUZUMAB; RISK; CM;
D O I：
10.1200/JCO.2015.63.8411
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：639 / +
页数：3
相关论文
共 50 条
  • [31] Trastuzumab and Chemotherapy May Be Appropriate for Small, Node-Negative, HER2-Positive Breast Cancer In Reply
    Connolly, Roisin M.
    Bardia, Aditya
    [J]. ONCOLOGIST, 2012, 17 (10): : E34 - E34
  • [32] Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer
    McArthur, Heather L.
    Mahoney, Kathleen M.
    Morris, Patrick G.
    Patil, Sujata
    Jacks, Lindsay M.
    Howard, Jane
    Norton, Larry
    Hudis, Clifford A.
    [J]. CANCER, 2011, 117 (24) : 5461 - 5468
  • [33] PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer
    Elisa Agostinetto
    Lieveke Ameye
    Samuel Martel
    Philippe Aftimos
    Noam Pondé
    Christian Maurer
    Sarra El-Abed
    Yingbo Wang
    Malou Vicente
    Saranya Chumsri
    Judith Bliss
    Judith Kroep
    Marco Colleoni
    Fausto Petrelli
    Lucia Del Mastro
    Alvaro Moreno-Aspitia
    Martine Piccart
    Marianne Paesmans
    Evandro de Azambuja
    Matteo Lambertini
    [J]. npj Breast Cancer, 8
  • [34] The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer
    Mette S. van Ramshorst
    Margriet van der Heiden-van der Loo
    Gwen M. H. E. Dackus
    Sabine C. Linn
    Gabe S. Sonke
    [J]. Breast Cancer Research and Treatment, 2016, 158 : 361 - 371
  • [35] The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer
    van Ramshorst, Mette S.
    van der Heiden-van der Loo, Margriet
    Dackus, Gwen M. H. E.
    Linn, Sabine C.
    Sonke, Gabe S.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2016, 158 (02) : 361 - 371
  • [36] Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib
    Kourie, Hampig Raphael
    El Rassy, Elie
    Clatot, Florian
    de Azambuja, Evandro
    Lambertini, Matteo
    [J]. ONCOTARGETS AND THERAPY, 2017, 10 : 3363 - 3372
  • [37] Spotlight on trastuzumab in the management of HER2-positive metastatic and early-stage breast cancer
    Plosker, Greg L.
    Keam, Susan J.
    [J]. BIODRUGS, 2006, 20 (04) : 259 - 262
  • [38] Clinical Outcomes in Breast Cancer Patients with HER2-Positive, Node-Negative Tumors (≤3 cm)
    Iwamoto, Naoko
    Aruga, Tomoyuki
    Horiguchi, Shinichiro
    [J]. BREAST CARE, 2022, 17 (04) : 356 - 362
  • [39] PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer
    Agostinetto, Elisa
    Ameye, Lieveke
    Martel, Samuel
    Aftimos, Philippe
    Ponde, Noam
    Maurer, Christian
    El-Abed, Sarra
    Wang, Yingbo
    Vicente, Malou
    Chumsri, Saranya
    Bliss, Judith
    Kroep, Judith
    Colleoni, Marco
    Petrelli, Fausto
    Del Mastro, Lucia
    Moreno-Aspitia, Alvaro
    Piccart, Martine
    Paesmans, Marianne
    de Azambuja, Evandro
    Lambertini, Matteo
    [J]. NPJ BREAST CANCER, 2022, 8 (01)
  • [40] Spotlight on Trastuzumab in the Management of HER2-Positive Metastatic and Early-Stage Breast Cancer
    Greg L. Plosker
    Susan J. Keam
    [J]. BioDrugs, 2006, 20 : 259 - 262
12345